RXRX sits at 30% short interest—pretty wild positioning right there. They just dropped some encouraging data on their first AI-developed drug candidate, which is honestly a big deal for the sector.

Now here's the catch: they burn cash like crazy and dilute shareholders whenever they need funding. That's the risk you're signing up for.

But think about this setup. Heavy shorts, positive catalyst, constant share dilution creating tension... classic ingredients for an explosive short squeeze if sentiment flips.

Oh, and Cramer's going full bear mode on this one. 🚀

You know what that usually means in this market.